Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers

被引：0
|
作者：
Juretzka, M. M. [1 ]
Aghajanian, C. [1 ]
Hensley, M. L. [1 ]
Tew, W. P. [1 ]
Spriggs, D. [1 ]
Konner, J. [1 ]
Chiang, A. C. [1 ]
Pezzulli, S. [1 ]
Kim, M. [1 ]
Sabbatini, P. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5564
引用
收藏
页数：2
相关论文
共 31 条
  • [1] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sharma, Sunil
    Freeman, Burgess
    Turner, Jeanette
    Symanowski, James
    Manno, Phillip
    Berg, William
    Vogelzang, Nicholas
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 63 - 65
  • [2] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sunil Sharma
    Burgess Freeman
    Jeanette Turner
    James Symanowski
    Phillip Manno
    William Berg
    Nicholas Vogelzang
    Investigational New Drugs, 2009, 27 : 63 - 65
  • [3] A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC).
    Schroder, W.
    Campone, M.
    Abadie, S.
    Witteveen, P.
    Viens, P.
    Jalava, T.
    Palacay-Radona, M.
    Bilic, S.
    Laurent, D.
    Du Bois, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 274S - 274S
  • [4] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E. G.
    Younger, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B. P.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E.
    Foster, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temazolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).
    Reardon, D
    Friedman, H
    Yung, WKA
    Brada, M
    Conrad, C
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Chen, B
    Laurent, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 110S - 110S
  • [7] Antiangiogeness as new treatment modality in ovarian cancer: a phase lb, open label, safety and pharmacokinetics (PK) study of escalating doses of PTK787/ZK222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (pts) with stage IC to IV epithelial ovarian cancer
    Schroeder, W.
    Abadie, S.
    Witteveen, P. O.
    Campone, M.
    Viens, P.
    Jalava, T.
    Masson, E.
    Bilic, S.
    Chlistalla, A.
    du Bois, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 273 - 273
  • [8] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme
    Resardon, David
    Friedman, H.
    Brada, M.
    Conrad, C.
    Provenzaie, J.
    Jackson, E.
    Serajuddin, H.
    Chen, B.
    Laurent, D.
    Yung, W.
    ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207
  • [9] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)
    Reardon, D
    Friedman, H
    Brada, N
    Conrad, C
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Chen, B
    NEURO-ONCOLOGY, 2004, 6 (04) : 381 - 381
  • [10] A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to IV epithelial ovarian cancer.
    Schroder, W
    Witteveen, E
    Abadie, S
    Campone, M
    Viens, P
    Jalava, T
    Masson, E
    Chlistalla, A
    Du Bois, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 465S - 465S
1234